Abstract
Based on fair quality Level 3 evidence, Lu et al.(1) note that glatiramer acetate (GA) exposure was not associated with lower mean birthweight, lower mean gestational age, preterm birth (37 weeks), congenital anomaly, or spontaneous abortion. However, GA was given an indeterminate recommendation because further research is needed. The results are not compelling: 3 of the 4 existing human studies of GA were small case series.(1.)
Publication types
-
Letter
-
Review
-
Systematic Review
MeSH terms
-
Animals
-
Female
-
Glatiramer Acetate
-
Humans
-
Multiple Sclerosis / drug therapy*
-
Multiple Sclerosis / epidemiology
-
Peptides / adverse effects
-
Peptides / therapeutic use*
-
Pregnancy
-
Pregnancy Complications / drug therapy*
-
Pregnancy Complications / epidemiology
-
Prenatal Exposure Delayed Effects / chemically induced
-
Prenatal Exposure Delayed Effects / epidemiology
Substances
-
Peptides
-
Glatiramer Acetate